Piper Sandler Maintains Overweight on TransMedics Gr, Raises Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on TransMedics Group (NASDAQ:TMDX) and raises the price target from $120 to $170.

July 15, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler's analyst Matt O'Brien has maintained an Overweight rating on TransMedics Group and increased the price target from $120 to $170.
The increase in the price target from $120 to $170 by a reputable analyst at Piper Sandler is a strong positive signal for investors. The Overweight rating suggests that the stock is expected to outperform the market, likely leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100